Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells
| Autor: | Zhiming Gui, Shaohua Zeng, Hanliang Zhu, Dong Yang, Shujue Li, Xiaolu Duan, Zhenzhen Kong, Yeping Liang, Wenqi Wu, George Iliakis |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Male
Small interfering RNA Poly (ADP-Ribose) Polymerase-1 Biophysics Medizin Antineoplastic Agents FOXO1 Docetaxel Poly(ADP-ribose) Polymerase Inhibitors urologic and male genital diseases Biochemistry PARP1 Transcription (biology) Cell Line Tumor Transcriptional regulation medicine Humans Phosphorylation RNA Small Interfering Molecular Biology Protein kinase B Cellular Senescence Epidermal Growth Factor Forkhead Box Protein O1 Chemistry Prostatic Neoplasms RNA Forkhead Transcription Factors Cell Biology Drug Resistance Neoplasm Gene Knockdown Techniques Cancer research Benzimidazoles Taxoids Poly(ADP-ribose) Polymerases Proto-Oncogene Proteins c-akt Signal Transduction medicine.drug |
| Popis: | Though poly(ADP-ribose) polymerase 1 (PARP1) inhibitors have benefits in combination with radiotherapy in prostate cancers, few is known about the exactly role and underlying mechanism of PARP1 in combination with chemotherapy agents. Here our data revealed that inhibition of PARP1 by small interfering RNA (siRNA) could enhance docetaxel's activity against PC3 cells, which is associated with an accelerate repression of EGF/Akt/FOXO1 signaling pathway. Our results provide a novel role of PARP1 in transcription regulation of EGFR/Akt/FOXO1 signaling pathway and indicate that PARP1 siRNA combined with docetaxel can be an innovative treatment strategy to potentially improve outcomes in CRPC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|